Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
NEW YORK, Jan. 22, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Vital Therapies, Inc. (NASDAQ: VTL) securities from April 17, 2014 through August 21, 2015 all dates inclusive (the “Class Period”) of the February 1, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Vital Therapies investors under the federal securities laws.
To join the Vital Therapies class action, go to the website at http://www.rosenlegal.com/cases-671.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose material information regarding Vital Therapies’ ELAD System studies, VTI-208, VTI-210, and VTI-212, including: (1) the studies’ independent significance; (2) the degree to which the studies were interrelated; and (3) that in the case of the failure of the VTI-208 trial, Vital Therapies would not continue the VTI-210 trial. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-671.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] www.rosenlegal.com
